Imbria Pharmaceuticals is a private, clinical-stage biotechnology company pioneering a novel approach to cardiovascular disease by targeting cardiac energy metabolism. Its lead asset, ninerafaxstat, is in Phase 2b development for non-obstructive hypertrophic cardiomyopathy (nHCM) and has shown promise in Phase 2a trials for cardiometabolic heart failure with preserved ejection fraction (HFpEF). The company is well-capitalized following a $57.5 million Series B financing extension in late 2025 and is led by a seasoned management team with deep cardiovascular and drug development expertise.
CardiovascularMetabolic Diseases
Technology Platform
Small molecule platform targeting cardiac energy metabolism via partial fatty acid oxidation (pFOX) inhibition to improve myocardial metabolic efficiency.
Funding History
3
Total raised:$227.5M
Series B$57.5MUndisclosed
Series B$107MCormorant Asset Management
Series A$63MAtlas Venture
Opportunities
Ninerafaxstat has blockbuster potential in the large, underserved HFpEF market and could be a first-in-class therapy for nHCM, a rare disease with no approved treatments.
Success in either indication would validate the novel cardiac metabolism platform, enabling expansion into other cardiovascular conditions with energetic impairment.
A strategic partnership with a larger pharma company for later-stage development or ex-US commercialization is a likely near-to-mid-term opportunity.
Risk Factors
High clinical development risk as the company's value is tied to a single asset (ninerafaxstat) currently in mid-stage trials; failure in the ongoing Phase 2b FORTITUDE-HCM trial would be a major setback.
The novel metabolic mechanism, while promising, is unproven in large, registrational studies and faces competition from other approaches in both nHCM and HFpEF.
As a private, pre-revenue company, Imbria faces financing risk and will require significant additional capital to advance to Phase 3 and commercialization.
Competitive Landscape
In nHCM, Imbria's ninerafaxstat is a first-in-class metabolic modulator, while competitors like Cytokinetics (aficamten for oHCM) and Bristol Myers Squibb (mavacamten for oHCM) target myocardial contractility. In the broader HFpEF space, competition is intense with recent SGLT2 inhibitor approvals (e.g., dapagliflozin) setting a new standard of care, and other novel mechanisms in development. Imbria's differentiation lies in its unique foundational hypothesis of correcting cardiac energetics.
